After a year on Byetta, Mendosa had dropped to 201 pounds and trimmed 16 inches from his waist
GLP-1 drugs show how quickly innovation can outpace policy, how cost pressures are resolved through access restrictions, and how deeply entrenched inequities shape who benefits from medical progress
Current Research and Clinical Evidence Clinical trials have shown that administering lower doses of semaglutide and tirzepatide not only results in significant weight loss but also minimizes the occurrence of side effects, making it a promising avenue for treatment
Retrieved from Ye, Y., Liu, X., Wu, N., et al
That is over a year to reach peak results
However, its main approved use is blood sugar control in type 2 diabetes